Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Osamu Morimura

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Biochemical and Biophysical Research Communications|May 21, 2017
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical modelsOsamu Morimura, Toshiyuki Minami, Takashi Kijima, et al.
Biochemical and Biophysical Research Communications|September 28, 2019
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrestHirotoshi Ishigaki, Toshiyuki Minami, Osamu Morimura, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancerYuhei Kinehara, Toshiyuki Minami, Takashi Kijima, et al.
Scientific Reports|September 17, 2013
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesisToshiyuki Minami, Takashi Kijima, Satoshi Kohmo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
JTO Clinical and Research Reports|March 19, 2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter StudyAkito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, et al.
Cancer Cell International|January 6, 2026
Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancerKinnosuke Matsumoto, Yoshimi Noda, Kensuke Hachiya, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Biochemical and Biophysical Research Communications|May 21, 2017
Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical modelsOsamu Morimura, Toshiyuki Minami, Takashi Kijima, et al.
Biochemical and Biophysical Research Communications|September 28, 2019
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrestHirotoshi Ishigaki, Toshiyuki Minami, Osamu Morimura, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancerYuhei Kinehara, Toshiyuki Minami, Takashi Kijima, et al.
Scientific Reports|September 17, 2013
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesisToshiyuki Minami, Takashi Kijima, Satoshi Kohmo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
JTO Clinical and Research Reports|March 19, 2026
Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter StudyAkito Miyazaki, Kinnosuke Matsumoto, Motohiro Tamiya, et al.
Cancer Cell International|January 6, 2026
Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancerKinnosuke Matsumoto, Yoshimi Noda, Kensuke Hachiya, et al.
JTO Clinical and Research Reports|October 27, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLCKensuke Kanaoka, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 25, 2026
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancerKinnosuke Matsumoto, Yuji Yamamoto, Takayuki Shiroyama, et al.
Pageof 4